The Emerging Role of Interleukin 1β (IL-1β) in Cancer Cachexia

被引：48

作者：

Laird, Barry J. ^{[1
]}

McMillan, Donald ^{[2
]}

Skipworth, Richard J. E. ^{[3
]}

Fallon, Marie T. ^{[1
]}

Paval, D. Robert ^{[5
]}

McNeish, Iain ^{[4
]}

Gallagher, Iain J. ^{[5
]}

机构：

[1] Univ Edinburgh, Insitute Genet & Canc, Crewe Rd, Edinburgh EH4 2XR, Midlothian, Scotland

[2] Univ Glasgow, Dept Surg Sci, Glasgow Royal Infirm, Glasgow, Lanark, Scotland

[3] Royal Infirm Edinburgh NHS Trust, Clin Surg, Edinburgh, Midlothian, Scotland

[4] Imperial Coll London, Div Canc, Dept Surg & Canc, London, England

[5] Univ Stirling, Fac Hlth Sci & Sport, Stirling, Scotland

来源：

INFLAMMATION | 2021年 / 44卷 / 04期

关键词：

Inflammation; Cachexia; Interleukin-1; beta; SYSTEMIC INFLAMMATORY RESPONSE; PERFORMANCE STATUS; LUNG-CANCER; WEIGHT-LOSS; ASSOCIATION; SYMPTOMS; PATHWAYS; OUTCOMES; IL-1;

D O I：

10.1007/s10753-021-01429-8

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Treatment of cancer cachexia remains an unmet need. The host-tumour interface and the resulting sequestration of the pro-inflammatory cytokine Il-1 beta is critical in cachexia development. Neuroinflammation mediated via IL-1 beta through the hypothalamic pituitary axis results in increased muscle proteolysis and adipose lipolysis, thus creating a prolonged stress-like environment with loss of appetite and increased resting energy expenditure. Recent trials using a monoclonal antibody targeting IL-1 beta, canakinumab, have shown a potential role in lung cancer; however, a potential role of targeting IL-1 beta to treat cachexia in patients with lung cancer is unclear, yet the underlying pathophysiology provides a sound rationale that this may be a viable therapeutic approach.

引用

页码：1223 / 1228

页数：6

共 56 条

[41] Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial [J].

Ridker, Paul M. ;

MacFadyen, Jean G. ;

Thuren, Tom ;

Everett, Brendan M. ;

Libby, Peter ;

Glynn, Robert J. .

LANCET, 2017, 390 (10105) :1833-1842

[42] Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? [J].

Ross, PJ ;

Ashley, S ;

Norton, A ;

Priest, K ;

Waters, JS ;

Eisen, T ;

Smith, IE ;

O'Brien, MER .

BRITISH JOURNAL OF CANCER, 2004, 90 (10) :1905-1911

[43] Regulation of agouti-related protein messenger ribonucleic acid transcription and peptide secretion by acute and chronic inflammation [J].

Scarlett, Jarrad M. ;

Zhu, Xinxia ;

Enriori, Pablo J. ;

Bowe, Darren D. ;

Batra, Ayesha K. ;

Levasseur, Peter R. ;

Grant, Wilmon F. ;

Meguid, Michael M. ;

Cowley, Michael A. ;

Marks, Daniel L. .

ENDOCRINOLOGY, 2008, 149 (10) :4837-4845

[44] Regulation of central melanocortin signaling by interleukin-1β [J].

Scarlett, Jarrad M. ;

Jobst, Erin E. ;

Enriori, Pablo J. ;

Bowe, Darren D. ;

Batra, Ayesha K. ;

Grant, Wilmon F. ;

Cowley, Michael A. ;

Marks, Daniel L. .

ENDOCRINOLOGY, 2007, 148 (09) :4217-4225

[45] Is IL-6 the best pro-inflammatory biomarker of clinical outcomes of cancer cachexia? [J].

Scheede-Bergdahl, Celena ;

Watt, Heather L. ;

Trutschnigg, Barbara ;

Kilgour, Robert D. ;

Haggarty, Allison ;

Lucar, Enriqueta ;

Vigano, Antonio .

CLINICAL NUTRITION, 2012, 31 (01) :85-88

[46] Prognosis in advanced lung cancer - A prospective study examining key clinicopathological factors [J].

Simmons, Claribel P. ;

Koinis, Filippos ;

Fallon, Marie T. ;

Fearon, Kenneth C. ;

Bowden, Jo ;

Solheim, Tora S. ;

Gronberg, Bjorn Henning ;

McMillan, Donald C. ;

Gioulbasanis, Ioannis ;

Laird, Barry J. .

LUNG CANCER, 2015, 88 (03) :304-309

[47] A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer [J].

Solheim, Tora S. ;

Laird, Barry J. A. ;

Balstad, Trude Rakel ;

Stene, Guro B. ;

Bye, Asta ;

Johns, Neil ;

Pettersen, Caroline H. ;

Fallon, Marie ;

Fayers, Peter ;

Fearon, Kenneth ;

Kaasa, Stein .

JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2017, 8 (05) :778-788

[48] Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study [J].

Sota, Jurgen ;

Vitale, Antonio ;

Insalaco, Antonella ;

Sfriso, Paolo ;

Lopalco, Giuseppe ;

Emmi, Giacomo ;

Cattalini, Marco ;

Manna, Raffaele ;

Cimaz, Rolando ;

Priori, Roberta ;

Talarico, Rosaria ;

de Marchi, Ginevra ;

Frassi, Micol ;

Gallizzi, Romina ;

Soriano, Alessandra ;

Alessio, Maria ;

Cammelli, Daniele ;

Maggio, Maria Cristina ;

Gentileschi, Stefano ;

Marcolongo, Renzo ;

La Torre, Francesco ;

Fabiani, Claudia ;

Colafrancesco, Serena ;

Ricci, Francesca ;

Galozzi, Paola ;

Viapiana, Ombretta ;

Verrecchia, Elena ;

Pardeo, Manuela ;

Cerrito, Lucia ;

Cavallaro, Elena ;

Olivieri, Alma Nunzia ;

Paolazzi, Giuseppe ;

Vitiello, Gianfranco ;

Maier, Armin ;

Silvestri, Elena ;

Stagnaro, Chiara ;

Valesini, Guido ;

Mosca, Marta ;

de Vita, Salvatore ;

Tincani, Angela ;

Lapadula, Giovanni ;

Frediani, Bruno ;

De Benedetti, Fabrizio ;

Iannone, Florenzo ;

Punzi, Leonardo ;

Salvarani, Carlo ;

Galeazzi, Mauro ;

Angotti, Rossella ;

Messina, Mario ;

Tosi, Gian Marco .

CLINICAL RHEUMATOLOGY, 2018, 37 (08) :2233-2240

[49] Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials [J].

Temel, Jennifer S. ;

Abernethy, Amy P. ;

Currow, David C. ;

Friend, John ;

Duus, Elizabeth M. ;

Yan, Ying ;

Fearon, Kenneth C. .

LANCET ONCOLOGY, 2016, 17 (04) :519-531

[50] Cancer cachexia [J].

Tisdale, MJ .

LANGENBECKS ARCHIVES OF SURGERY, 2004, 389 (04) :299-305

← 1 2 3 4 5 6 →